Developer docs
API playgroundTry for free, no card

Search company profiles

ReViral

Full company profile

uuid0002dmq

Namestring
ReViral
Websiteurl
reviral.co.uk
Company typeenum
Private
Founded yearint
2011
Descriptiontext

ReViral is a privately held clinical-stage biotechnology company founded in 2011 and headquartered in Stevenage, United Kingdom. The company develops antiviral therapies intended for patient treatment, with the available context indicating a focus on respiratory viral infections. Operating with a small team of 11-50 employees, ReViral follows a development-stage biotech model centered on proprietary antiviral compounds advancing through clinical evaluation, rather than a commercial-stage pharmaceutical sales operation.

The company has financed its R&D through four private funding rounds between December 2014 and August 2020, raising approximately $121 million in total. Investor participation has included a consistent group of healthcare-focused institutional investors: Brace Pharma, Andera Partners, New Leaf Venture Partners, Novo Holdings/Ventures, OrbiMed, and Perceptive Advisors, with CR-CP Life Science Fund and Green Sands Equity joining the 2020 syndicate. The funding progression — from a $1M initial round (2014) to a $21M round (2015), a $55M Series B (2018), and a $44M Series C (2020) — signals sustained institutional confidence and a pipeline advancing through progressively more capital-intensive clinical stages.

Leadership combines founder-led scientific direction with experienced pharma executives. Co-founders Stuart Cockerill (Chief Scientific Officer) and Neil Mathews (Project Director) provide continuity of the original research vision, while Ken Powell serves as Executive Chairman and Brett Haumann as Chief Medical Officer. The business model is consistent with a clinical-stage biotech: no listed commercial products, no disclosed pricing, and revenue generation contingent on future regulatory approval, commercialization, or partnership/licensing. The supplied data does not include source-resolvable information on post-2020 corporate status.

Short descriptiontext

ReViral is a UK-based clinical-stage biotechnology company founded in 2011 that develops antiviral therapies for patients, having raised approximately $121 million across four private funding rounds from 2014 to 2020.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStevenage, United Kingdom
HQ citystring
Stevenage
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
antiviral therapeutics, RSV drug development, respiratory virus treatments, clinical-stage biotechnology, pharmaceutical R&D
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Antiviral Therapeutics
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ReViral is a clinical-stage biotechnology company that discovers and develops antiviral drug candidates targeting respiratory syncytial virus (RSV). The company's portfolio includes small-molecule fusion inhibitors and other antiviral agents intended to treat and prevent RSV infections in at-risk populations. ReViral operates primarily in the drug discovery and clinical development phases of pharmaceutical R&D.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available for ReViral in the source data. The domain reviral.co.uk contains content about a gambling/casino review website (Non GamStop Casinos), not a technology company. The other sources contain unrelated content about Pfizer and Innovent Biologics partnership, or blocked/error pages.

Product and service2 records
1RSV fusion inhibitor (lead clinical candidate)
CategoryAntiviral small-molecule therapeutics
2RSV antiviral discovery platform
CategoryAntiviral R&D platform
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ReViral

Antiviral Therapeuticsreviral.co.uk

ReViral is a UK-based clinical-stage biotechnology company founded in 2011 that develops antiviral therapies for patients, having raised approximately $121 million across four private funding rounds from 2014 to 2020.

What ReViral does

ReViral is a privately held clinical-stage biotechnology company founded in 2011 and headquartered in Stevenage, United Kingdom. The company develops antiviral therapies intended for patient treatment, with the available context indicating a focus on respiratory viral infections. Operating with a small team of 11-50 employees, ReViral follows a development-stage biotech model centered on proprietary antiviral compounds advancing through clinical evaluation, rather than a commercial-stage pharmaceutical sales operation.

The company has financed its R&D through four private funding rounds between December 2014 and August 2020, raising approximately $121 million in total. Investor participation has included a consistent group of healthcare-focused institutional investors: Brace Pharma, Andera Partners, New Leaf Venture Partners, Novo Holdings/Ventures, OrbiMed, and Perceptive Advisors, with CR-CP Life Science Fund and Green Sands Equity joining the 2020 syndicate. The funding progression — from a $1M initial round (2014) to a $21M round (2015), a $55M Series B (2018), and a $44M Series C (2020) — signals sustained institutional confidence and a pipeline advancing through progressively more capital-intensive clinical stages.

Leadership combines founder-led scientific direction with experienced pharma executives. Co-founders Stuart Cockerill (Chief Scientific Officer) and Neil Mathews (Project Director) provide continuity of the original research vision, while Ken Powell serves as Executive Chairman and Brett Haumann as Chief Medical Officer. The business model is consistent with a clinical-stage biotech: no listed commercial products, no disclosed pricing, and revenue generation contingent on future regulatory approval, commercialization, or partnership/licensing. The supplied data does not include source-resolvable information on post-2020 corporate status.

ReViral firmographics

Firmographics
Name
ReViral
Website
https://reviral.co.uk
Company type
Private
Founded year
2011
Headcount range
1–10 employees
Short description
ReViral is a UK-based clinical-stage biotechnology company founded in 2011 that develops antiviral therapies for patients, having raised approximately $121 million across four private funding rounds from 2014 to 2020.
Ownership category
akta.pro rank

ReViral industry classification

Industry
Product category
Antiviral Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antiviral therapeutics
  • RSV drug development
  • Respiratory virus treatments
  • Clinical-stage biotechnology
  • Pharmaceutical R&D

Where ReViral is headquartered

Location

Headquarters

HQ city
Stevenage
HQ country
United Kingdom
HQ region
Europe

Markets served

ReViral business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

ReViral product offering

Product offering

Core offering

ReViral is a clinical-stage biotechnology company that discovers and develops antiviral drug candidates targeting respiratory syncytial virus (RSV). The company's portfolio includes small-molecule fusion inhibitors and other antiviral agents intended to treat and prevent RSV infections in at-risk populations. ReViral operates primarily in the drug discovery and clinical development phases of pharmaceutical R&D.

Product overview

No product information available for ReViral in the source data. The domain reviral.co.uk contains content about a gambling/casino review website (Non GamStop Casinos), not a technology company. The other sources contain unrelated content about Pfizer and Innovent Biologics partnership, or blocked/error pages.

Differentiator

Problem solved

Functional benefit

Products and services

  • RSV fusion inhibitor (lead clinical candidate)
  • RSV antiviral discovery platform

Companies that use ReViral

Customer profile

Ideal customer profiles2 records

ReViral technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ReViral partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

ReViral competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key highlights5 records

Customer concentration

ReViral social profiles

Digital presence

ReViral financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ReViral leadership team

Management profile

Number of profiles

Profiles4 records

ReViral funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ReViral M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ReViral

What does ReViral do?

ReViral is a clinical-stage biotechnology company that discovers and develops antiviral drug candidates targeting respiratory syncytial virus (RSV). The company's portfolio includes small-molecule fusion inhibitors and other antiviral agents intended to treat and prevent RSV infections in at-risk populations. ReViral operates primarily in the drug discovery and clinical development phases of pharmaceutical R&D.

When was ReViral founded?

ReViral was founded in 2011. It employs 1 to 10 people.

Where is ReViral based?

ReViral is headquartered in Stevenage, United Kingdom, in the Europe region.

Does ReViral have an API?

No public API is recorded for ReViral.

What industry is ReViral in?

ReViral's product category is Antiviral Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRespiratory Syncytial Virus Market to Surge at a CAGR of 13.1% During the Study Period (2019-2032), Predicts DelveInsightDelveInsight's market report projects the respiratory syncytial virus (RSV) market to grow at a CAGR of 13.1% from 2019 to 2032, reaching approximately USD 850 million in market size in 2021 across the 7MM (United States, EU-4, United Kingdom, and Japan), with around 4.2 million incident cases reported in 2021. The report identifies multiple vaccine candidates in development by companies including Pfizer, which completed its acquisition of ReViral in June 2022, and notes that CHMP recommended approval of Sanofi/AstraZeneca's nirsevimab (BEYFORTUS) for infant RSV prevention in Europe in September 2022. Key market growth drivers include increasing disease prevalence and upcoming therapeutic launches, while barriers include limited adult treatment options and lack of awareness.FierceBiotechPfizer snaps up rights to RSV therapy left behind in ReViral buy for $20MPfizer paid $20 million to LianBio for rights to develop and commercialize sisunatovir in Greater China, a therapy left out of its ReViral acquisition. The deal includes $135 million in milestones and tiered royalties, with Pfizer leading development and commercialization. Pfizer also has a priority review for its RSV vaccine, with a decision expected in May.News-MedicalThe applications of respiratory syncytial virus antigens and antibodies in therapeutic and immunological developmentPfizer's $525 million acquisition of ReViral's RSV therapy has spurred global interest in RSV treatments, as no approved vaccine exists. The article details RSV's impact, including 58,000 pediatric and 177,000 adult hospitalizations annually in the US, and reviews vaccine, drug, and diagnostic development using RSV antigens and antibodies.BenzingaWhat's Going On With Pfizer Stock Today? - Pfizer (NYSE:PFE)Pfizer Inc. shares rose following the announcement of its acquisition of clinical-stage biopharmaceutical company ReViral for up to $525 million. The deal includes ReViral's therapeutic candidates, notably sisunatovir, an oral inhibitor for respiratory syncytial virus (RSV) that has received Fast Track designation from the U.S. FDA.Barron'sPfizer Buys ReViral in Fight Against RSVPfizer acquired ReViral, a company focused on respiratory viruses. The acquisition targets ReViral's antiviral therapy for RSV, which is described as a key tool against the virus as vaccine efficacy wanes.ReutersPfizer boosts respiratory drug portfolio with ReViral purchasePfizer agreed to buy privately-held ReViral Ltd for up to $525 million, including milestone payments, to access experimental RSV therapies. The deal follows a $6.7 billion Arena Pharmaceuticals acquisition and adds four RSV candidates to Pfizer's pipeline.BioSpaceReViral Appoints Brett Haumann as Chief Medical OfficerReViral appointed Brett Haumann as Chief Medical Officer, bringing seven years of experience at Theravance Biopharma. He previously led development of revefenacin and RELVAR/BREO, and will focus on sisunatovir and the N-protein replication inhibitor program.BusinessCloudBioTech ReViral raises £33m in Series C financingBioTech firm ReViral closed a £33m ($44m) Series C funding round led by CR-CP Life Science Fund. The Hertfordshire-based company will use the proceeds to advance Phase 2 clinical development of its RSV inhibitor sisunatovir and progress its N-protein replication inhibitor program into Phase 1.FinSMEsAntiviral Drug Discovery and Development Company ReViral Raises US$55MReViral, a UK-based antiviral drug company, raised US$55M in a Series B led by New Leaf Venture Partners and Novo Ventures. The funds will advance its lead candidate RV521 into Phase IIa trials for RSV infections, with a paediatric trial expected soon.